| MeSH term | MeSH ID | Detail |
|---|---|---|
| Crohn Disease | D003424 | 12 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Sinusitis | D012852 | 9 associated lipids |
| Immunologic Deficiency Syndromes | D007153 | 8 associated lipids |
| Penile Diseases | D010409 | 2 associated lipids |
| Acquired Immunodeficiency Syndrome | D000163 | 12 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Vranes J et al. | Influence of subinhibitory concentrations of ceftazidime, ciprofloxacin and azithromycin on the morphology and adherence of P-fimbriated escherichia coli. | 1996 | J Chemother | pmid:8873829 |
| Laing RB et al. | Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. | 1996 | Int J STD AIDS | pmid:8876356 |
| Tansey MJ and Moe JB | Severe neutropenia and prophylactic doses of rifabutin. | 1996 | Lancet | pmid:8950911 |
| Sefton AM et al. | Azithromycin in the treatment of periodontal disease. Effect on microbial flora. | 1996 | J. Clin. Periodontol. | pmid:8951627 |
| Griffith DE et al. | Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. | 1996 | Clin. Infect. Dis. | pmid:8953085 |
| Clearance to market azithromycin as prevention for a common OI in advanced AIDS. | 1996 | AIDS Patient Care STDS | pmid:11361535 | |
| Brihmer C et al. | Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. | 1996 | Scand. J. Infect. Dis. | pmid:8953672 |
| Prophylactic antibiotic receives speedy FDA approval to reduce MAC disease in advanced HIV. | 1996 | AIDS Patient Care STDS | pmid:11361569 | |
| Van Bambeke F et al. | Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. | 1996 | Eur. J. Pharmacol. | pmid:8957238 |
| Azithromycin and OIs. | 1996 | AIDS Patient Care STDS | pmid:11361699 | |
| Montenez JP et al. | Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. | 1996 | Eur. J. Pharmacol. | pmid:8957239 |
| Prescott LM | Macrolides, azalides, and streptogrammins. | 1996 | J Int Assoc Physicians AIDS Care | pmid:11363516 |
| Currier J | Progress report: prophylaxis and therapy for MAC. | 1996 | AIDS Clin Care | pmid:11363599 |
| Tabbara KF et al. | Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. | 1996 | Ophthalmology | pmid:8637698 |
| Bertoni G et al. | Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. | 1996 | Am. J. Gastroenterol. | pmid:8607489 |
| Di Mario F et al. | Azithromycin for the cure of Helicobacter pylori infection. | 1996 | Am. J. Gastroenterol. | pmid:8607490 |
| Wittner M et al. | Atovaquone in the treatment of Babesia microti infections in hamsters. | 1996 | Am. J. Trop. Med. Hyg. | pmid:8780464 |
| Gerbaux C et al. | Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. | 1996 | FEBS Lett. | pmid:8830663 |
| Domingo S and Gamazo C | Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections. | 1996 | J Chemother | pmid:8835110 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Dupont C et al. | Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. | 1996 | J. Clin. Microbiol. | pmid:8748314 |
| Wildfeuer A et al. | Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. | 1996 | Antimicrob. Agents Chemother. | pmid:8787883 |
| Hicks P et al. | Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. | 1996 | J. Pediatr. | pmid:8765631 |
| Boran M et al. | Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. | 1996 | Transplant. Proc. | pmid:8769234 |
| Luft BJ et al. | Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. | 1996 | Ann. Intern. Med. | pmid:8610947 |
| Akita H et al. | [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8986553 |
| Nishimura T et al. | [Clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8986554 |
| Haruta T and Kobayashi Y | [Therapeutic efficacy of azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8986555 |
| Kuroda Y and Ito M | [Therapy with azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8986556 |
| Okamoto T and Sekiguchi T | [Clinical studies on azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8986557 |
| Toyonaga Y et al. | [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. | 1996 | Jpn J Antibiot | pmid:8988410 |
| Okumura A and Kuno K | [Pharmacokinetic and clinical evaluation of azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8988411 |
| Kobayashi Y et al. | [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. | 1996 | Jpn J Antibiot | pmid:8988412 |
| Furukawa S and Okada T | [A clinical evaluation of azithromycin in the treatment of pediatric infection]. | 1996 | Jpn J Antibiot | pmid:8988413 |
| Okada T et al. | [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8988414 |
| Ishida Y et al. | [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8988415 |
| Wilton LV et al. | A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. | 1996 | Br J Clin Pharmacol | pmid:8730972 |
| Adhikari P et al. | Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI) | 1996 | Indian J Med Sci | pmid:9057364 |
| Thylefors B | Trachoma--new opportunities to tackle an old problem. | 1996 | Br J Ophthalmol | pmid:9059262 |
| Three new studies expand understanding of MAC therapy. | 1996 | Am J Health Syst Pharm | pmid:8899122 | |
| Evans LA et al. | Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. | 1996 | Pharm. Res. | pmid:8899856 |
| O'Doherty B | Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. | 1996 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:8922571 |
| Griffith DE et al. | Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. | 1996 | Clin. Infect. Dis. | pmid:8922790 |
| Chulig I | [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. | 1996 | Antibiot. Khimioter. | pmid:8929112 |
| Kuznetsova SM | ["Sumamed in the treatment of urogenital infections"]. | 1996 | Antibiot. Khimioter. | pmid:8929115 |
| Cellesi C et al. | Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. | 1996 | J Chemother | pmid:8808714 |
| Watt B et al. | Comparative activity of azithromycin against clinical isolates of mycobacteria. | 1996 | J. Antimicrob. Chemother. | pmid:8889727 |
| Mashkilleyson AL et al. | Treatment of syphilis with azithromycin. | 1996 | Int J STD AIDS | pmid:8652720 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |